Danicopan (Voydeya®) is an oral complement factor D inhibitor that is being developed by
Alexion AstraZeneca Rare Disease as add-on treatment to ravulizumab or eculizumab for …

Therapeutic interventions in the complement system, a key immune‐inflammatory mediator
and contributor to a broad range of clinical conditions, have long been considered important …

Cardiovascular and metabolic diseases (CVMDs) constitute the principal causes of death
globally. Cardiovascular diseases (CVDs) constitute more than two-thirds of the deaths …

Myasthenia Gravis (MG) is a chronic disabling autoimmune disease caused by
autoantibodies to the neuromuscular junction (NMJ), characterized clinically by fluctuating …

This mini review spotlights the most promising treatments for geographic atrophy, the
advanced form of age-related macular degeneration, often resulting in severe and …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and potentially life-threatening
hematologic disorder caused by a somatic mutation in a relevant portion of hematopoietic …

We describe initial, current, and future aspects of complement activation and inhibition in the
rare hematological disease paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare but …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease in which blood
cells lack anchored proteins that regulate the complement system. The erythrocytes are then …

Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder
characterized by episodic hemolysis, with additional clinical manifestations including …

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, complement-associated,
haematological disorder. The level of knowledge about the disease and its management …